Key Points
- CEO August Troendle sold 10,880 Medpace shares at an average price of $620.40, generating approximately $6.75 million; he retains 504,273 shares valued at about $312.9 million.
- Medpace reported quarterly EPS of $4.25, exceeding estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
- Analysts maintain a consensus “Hold” rating, with an average price target of $595.20 versus the stock’s reported $624.20 price; institutional investors own 77.98% of outstanding shares.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 10,880 shares of the business's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $620.40, for a total transaction of $6,749,952.00. Following the completion of the transaction, the chief executive officer owned 504,273 shares in the company, valued at $312,850,969.20. This represents a 2.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Medpace Price Performance
Shares of Medpace stock opened at $624.20 on Tuesday. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The company has a market capitalization of $17.42 billion, a PE ratio of 36.59, a P/E/G ratio of 2.73 and a beta of 1.15. The business has a 50-day moving average of $587.74 and a 200-day moving average of $512.01.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business's revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on MEDP. TD Cowen raised their price target on Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. BMO Capital Markets increased their target price on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research report on Friday, July 24th. Robert W. Baird raised their target price on Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. Finally, Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $595.20.
Check Out Our Latest Report on Medpace
Institutional Trading of Medpace
Large investors have recently added to or reduced their stakes in the business. Johnson Financial Group Inc. bought a new stake in Medpace during the 2nd quarter valued at $27,000. Jones Financial Companies Lllp acquired a new position in Medpace during the 2nd quarter worth $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace in the second quarter worth $31,000. Kilter Group LLC bought a new position in shares of Medpace in the second quarter worth $31,000. Finally, Basecamp Wealth Advisors LLC increased its holdings in shares of Medpace by 187.5% during the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company's stock valued at $33,000 after purchasing an additional 45 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
